Biotech company BioMarin Pharmaceutical (NASDAQ: BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for.
BioMarin Pharmaceutical beat analysts’ revenue expectations by 4.8% last quarter, reporting revenues of $747.3 million, up 15.6% year on year. It was a stunning quarter for the company, with an impressive beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.
Is BioMarin Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting BioMarin Pharmaceutical’s revenue to grow 13.8% year on year to $738.1 million, improving from the 8.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.95 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BioMarin Pharmaceutical has missed Wall Street’s revenue estimates twice over the last two years.
Looking at BioMarin Pharmaceutical’s peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. AbbVie delivered year-on-year revenue growth of 8.4%, beating analysts’ expectations by 3.3%, and Gilead Sciences reported flat revenue, falling short of estimates by 2.1%. AbbVie traded up 6.6% following the results while Gilead Sciences was down 2.7%.
Read our full analysis of AbbVie’s results here and Gilead Sciences’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. BioMarin Pharmaceutical is down 6.6% during the same time and is heading into earnings with an average analyst price target of $96.87 (compared to the current share price of $63.48).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
